Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Apr 15, 2023; 15(4): 689-699
Published online Apr 15, 2023. doi: 10.4251/wjgo.v15.i4.689
Published online Apr 15, 2023. doi: 10.4251/wjgo.v15.i4.689
Adverse event | Any grade | Grade 3 | Grade 4 |
Cutaneous toxic effects | 25 (13.2) | 3 (1.6) | 2 (1.1) |
Mucositis | 8 (4.2) | 2 (1.1) | 1 (< 1) |
Rash | 7 (3.7) | 1 (< 1) | 1 (< 1) |
Pruritus | 10 (5.3) | 2 (1.1) | 0 (0) |
Diarrhea | 27 (14.2) | 4 (2.1) | 1 (< 1) |
Elevated transaminases | 35 (18.4) | 10 (5.3) | 2 (1.1) |
Hypothyroidism | 25 (13.2) | 4 (2.1) | 2 (1.1) |
Myocarditis | 3 (1.6) | 1 (< 1) | 2 (1.1) |
Hypoadrenocorticism | 5 (2.6) | 1 (< 1) | 0 (0) |
Proteinuria | 18 (9.5) | 5 (2.6) | 0 (0) |
Overall incidence | 138 (72.6) | 12 (6.3) | 7 (3.7) |
- Citation: Zhou JM, Xiong HF, Chen XP, Zhang ZW, Zhu LP, Wu B. Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study. World J Gastrointest Oncol 2023; 15(4): 689-699
- URL: https://www.wjgnet.com/1948-5204/full/v15/i4/689.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i4.689